Up ~135% on the year, growing revenue 34%, a $1.27B backlog — and it still trades at a deep discount to the value of its own China-listed subsidiary. A rare case where the trend, the growth, and the value all line up — if you can hold the China risk.
First gate: is it uptrending? Yes — unambiguously. ~135% YTD, leading its sector.
Before anything else: ACMR clears the trend gate cleanly. It's up ~135% year-to-date and ~159% over the trailing year, riding the broad semiconductor-equipment rally and its own order momentum. This isn't a "cheap stock waiting for a catalyst" — it's a stock already in a strong uptrend that also happens to screen cheap, which is the more favorable setup. The rest of this report is about whether the fundamentals and structure justify staying with the trend, not about trying to catch a falling knife.
The stock is clearly going up — more than doubled this year. That passes the first test (only ride things that are trending up). Everything below is about whether the business backs up the chart.
The cleaning and plating layer of chipmaking. Unglamorous, essential tools — and a Chinese-fab market-share story.
ACM makes the machines that clean and coat silicon wafers as chips are built — boring but necessary gear every chip factory needs. Its main customers are China's fast-growing chip factories, which are spending heavily to become independent of foreign suppliers. ACM is winning more of that business and expanding into new tool types and new countries.
Real growth, watch the margin. Top line and orders are strong; gross margin is drifting down on mix.
| Metric (Q1 2026) | Value | Read |
|---|---|---|
| Revenue | $231.3M · +34% YoY | strong, broad-based |
| New orders signed | +65% YoY | forward fuel — the best signal |
| Backlog | $1.27B · +34% YoY | visibility into 2026–27 |
| ECP revenue | +205% | fastest-growing product |
| Gross margin | 46.5% (was 48.2%) | drifting down on mix/competition |
| Non-GAAP EPS | $0.37 (was $0.49) | down YoY despite revenue growth |
| 2026 revenue guide | $1.08–1.175B · ~21–30% | reaffirmed |
| Market cap | ~$3.4B | small-cap, ~3x sales |
The growth is real and order-backed: +34% revenue, +65% new orders, a $1.27B backlog, and a reaffirmed ~21–30% 2026 guide. The blemish is the margin and earnings line — gross margin slipped to ~46.5% and non-GAAP EPS actually fell year-over-year ($0.37 vs $0.49), as a mix shift toward newer/lower-margin tools and competitive pricing in cleaning bites. Management guides gross margin to a 42–48% range for 2026 and expects recovery as new products ramp. So this is a top-line-and-orders story with a margin question attached — the revenue inflection is clear, the earnings inflection lags it. Worth noting the Q1 EPS beat included a one-time ~$17M gain, so underlying profitability is a touch softer than the headline.
Sales jumped 34% and new orders 65% — genuinely strong, with a big backlog giving visibility. The weak spot: profit margins slipped and earnings per share actually fell versus last year, because the new products it's selling carry thinner margins and competition is pressuring prices. Growth is clearly there; turning it into more profit is the open question.
The weird, central fact. ACMR trades at a deep discount to just its stake in its own China-listed subsidiary.
This is what makes ACMR genuinely unusual — and it's the heart of the value case. The structure: ACMR (the US-listed parent) owns ~82% of ACM Shanghai, which is separately listed on China's STAR Market (SSE: 688082). Because ACM Shanghai trades publicly, you can mark the value of ACMR's stake directly — and for stretches, ACMR's entire market cap has been worth less than ~30% of the value of that stake alone, i.e. a ~70%+ discount to its China-subsidiary holding, before crediting any of the US business, cash, or other assets.
| The pieces | What it means |
|---|---|
| ACM Shanghai (STAR-listed) | The operating China business — publicly valued, ACMR owns ~82% |
| The discount | ACMR has traded at a ~70%+ discount to the value of just that stake |
| Why it exists | China-risk holdco discount, US/China listing arbitrage, perceived geopolitical/governance overhang |
| The catalyst | Activists (Kerrisdale + Steamboat) pushing a Hong Kong listing + capital-structure moves to close the gap |
Two well-known funds, Kerrisdale Capital and Steamboat Capital, have gone public pushing management to close this gap — even signaling willingness to act as anchor investors in a potential Hong Kong listing of the China business. The bull logic: the sum-of-parts is worth dramatically more than the stock, and a re-listing/restructuring is a hard catalyst to force the market to recognize it. The skeptical view: holdco discounts on China-exposed dual-listed structures can persist for years precisely because the risks (capital controls, can you actually repatriate the value, geopolitics) are real, not imaginary. Either way, the discount is the single most distinctive part of the ACMR thesis — you're buying a growing tool company and a potential value-unlock catalyst.
Here's the strange part: ACM Research owns 82% of a Chinese company that trades on its own stock exchange in China. You can look up exactly what that 82% stake is worth — and at times, the entire US-listed ACMR stock has been worth far less than just that stake, like buying a wallet for $30 that has $100 cash inside. Activist investors are pushing to fix this gap (possibly via a Hong Kong listing). It's a real potential bargain — but the discount exists because getting that value out of China isn't guaranteed.
How a NAV-discount analyst frames it. The "asset-backed" angle — and the catch that keeps it cheap.
One independent AI/semiconductor-supply-chain analyst who hunts specifically for NAV-discount names that also have standalone AI growth recently flagged ACMR as a prime — even "extreme" — example of the setup. The framing is worth capturing because it sharpens the holdco-discount math into an actual thesis:
- The asset base: ACMR holds roughly ~$18B worth of value via its stake in ACM Shanghai — against a US-listed market cap a fraction of that. A large, tangible discount to net asset value.
- Why the discount is rational: "I don't think they can fully liquidate it, which is why it trades at a discount to NAV." The China assets can't simply be sold and upstreamed — so the gap isn't pure free money.
- Why the standalone AI vertical matters: precisely because the China stake is hard to monetize, the US/parent expansion is the key independent growth driver — the thing that can re-rate the stock without needing to crack open the China value. The analyst wants that "US parent expansion to take off in H2 2026."
- The "de-risked" claim: these asset-heavy, discount-to-NAV names are seen as slightly more de-risked than pure-story stocks — because there's a real, valued asset base underneath, even at a discount.
The figures check out against current data: ACM Shanghai's A-shares (SSE: 688082) have run to near 52-week highs (market cap ~¥183B ≈ ~$25B), putting ACMR's ~73.5% stake around ~$18B — versus a US market cap far below that. So the ~$18B-stake-vs-single-digit-billions-cap framing is real. But two honest caveats sharpen it: first, the discount persists for a concrete reason the analyst names — Chinese capital controls, SAFE approval, a 10% withholding tax, and the fact that ACMR holders can never directly own the 688082 shares — so the NAV is real but partially trapped. Second, the A-shares are themselves richly valued (Chinese retail bids semi-equipment names to 40–100x P/E), which means the discount could close partly by 688082 falling rather than ACMR rising. The independent take is directionally sound — asset-backed, discounted, with a standalone-AI catalyst — but "asset-backed" is not "asset-accessible," and that distinction is the whole reason the discount has survived the entire cycle.
An outside analyst who specializes in these "trades-below-its-assets" situations highlighted ACMR as a standout: it owns ~$18B worth of its Chinese subsidiary but trades far below that. Her key point — and it's a fair one — is that the discount exists because you can't easily get that China money out, which is exactly why the US business growing on its own (especially in late 2026) is what really matters. The honest catch: the assets are real but partly stuck in China, and the Chinese shares are themselves pricey — so the gap might close by them falling, not just by ACMR rising.
The whole bear case in one word. The growth engine and the existential risk are the same thing.
There's no way around it: ACM's revenue is overwhelmingly tied to Chinese semiconductor fabs, so US/China policy is the risk model. The same Chinese self-sufficiency drive that fuels the order book also puts ACM in the crosshairs of export controls and geopolitical escalation. The specific exposures:
▲ Why China is the engine
- Self-sufficiency boom: Chinese fabs (SMIC, Hua Hong) at 95–109% utilization, expanding capacity aggressively.
- Domestic-preference tailwind: Chinese fabs increasingly favor domestic-linked suppliers like ACM over US/Western WFE.
- AI pull: China GPU self-sufficiency targeted ~50% by 2027 — huge WFE spend behind it.
- Share gains: ACM grew 15% in 2025 vs a flat China WFE market — outgrowing its end market.
▼ Why China is the risk
- Export controls: tighter US rules could restrict ACM's access to US components or customers.
- Geopolitical binary: Taiwan/China escalation, entity-list actions, or sanctions are tail risks that hit hard.
- Repatriation: value trapped in the China subsidiary may be hard to move to US holders — part of why the discount persists.
- Data/governance: cross-border data rules, dual-listing governance, and disclosure concerns.
- Concentration: a few large Chinese customers drive much of revenue.
This is a genuinely binary-tinged risk, which is different from the ordinary execution risk in most names. In the base case (no major policy shock), ACM keeps compounding and the discount potentially narrows — a great outcome. In the tail case (serious export-control or geopolitical escalation), the China exposure that's driving the growth becomes the thing that impairs it. You can't own ACMR without underwriting that you're comfortable holding concentrated China-semiconductor risk. The uptrend says the market is currently weighting the bull engine over the bear tail — but the tail is real and won't show up gradually.
ACM's growth comes almost entirely from China's chip factories — which is great while China is spending big, but dangerous if the US tightens trade rules or tensions escalate. The same thing that makes it grow could be the thing that breaks it. It's an on/off risk, not a gradual one, so you have to be genuinely OK holding heavy China exposure to own it.
Two scores. Business + trend: 8/10 · risk-adjusted for China: 6.5/10.
| Dimension | Grade | Why |
|---|---|---|
| Trend | A | +135% YTD, leading the semi-equipment rally — clears the gate |
| Revenue / orders | A− | +34% rev, +65% orders, $1.27B backlog, ~21–30% guide |
| Valuation (sum-of-parts) | A | Deep discount to its own China-sub stake — activist catalyst |
| Margins / earnings | C+ | GM ~46% and slipping; non-GAAP EPS down YoY |
| China / geopolitical risk | C− | Overwhelming China exposure — binary policy tail-risk |
| Balance sheet | A− | Well-capitalized, profitable, raising capital for ACM Shanghai |
On business-and-trend alone, ACMR is an 8 — it's exactly the kind of name the "only-uptrending" rule is meant to find: a strong, order-backed grower already in an uptrend that also trades at a sum-of-parts discount with an activist catalyst. The risk-adjusted score is a 6.5 because the China concentration is a genuine binary overhang and the margin trend is soft — you're being paid (via the discount and the growth) to take a real, non-diversifiable geopolitical risk. The gap between the two scores is the China risk, quantified. For a trend-follower comfortable with China-semi exposure, this is a high-quality uptrend with a value kicker; for anyone who can't stomach a policy-shock tail, the discount will never feel cheap enough.
Judged on growth and momentum, it's a strong 8 — just the kind of rising, cheap-on-the-parts stock worth riding. Adjusted for the heavy China risk and softening margins, it's a 6.5. The difference between those two numbers is basically "how much does the China danger worry you." If you're fine holding China chip exposure, it's attractive; if not, skip it.
John's read. Passes the trend gate with a value kicker — sized for the China tail-risk.
- It clears the only-uptrending rule cleanly. +135% YTD, leading the semi-equipment group, with the fundamentals behind it (+34% revenue, +65% orders, $1.27B backlog). This isn't a falling knife — it's a strong trend that also screens cheap, which is the best combination.
- The holdco discount is the edge. Owning ~82% of STAR-listed ACM Shanghai, ACMR has traded at a ~70%+ discount to just that stake. With Kerrisdale and Steamboat pushing a Hong Kong listing to close the gap, you get a growing tool company plus a potential value-unlock catalyst. That's a genuinely differentiated setup.
- The margin softening is the yellow flag. Gross margin slipping to ~46% and non-GAAP EPS down YoY says the growth is coming at the cost of profitability — mix and price competition. I want to see margins stabilize as ECP/new products ramp; that's the metric that turns the revenue inflection into an earnings one.
- The China risk is the whole bear case, and it's binary. The same Chinese-fab demand driving the order book is an export-control/geopolitical tail-risk that won't show up gradually. You can't own this without being genuinely comfortable holding concentrated China-semi exposure.
- How I'd play it: ride the trend, size for the tail. It's an 8 on business-and-trend, a 6.5 after the China haircut — so it's a real position, not a back-up-the-truck one. Stay with it while the uptrend holds and the order book grows; respect that a policy shock is the one thing that breaks it instantly. Trend + value + catalyst on the upside, binary China risk on the downside — size accordingly.
Want the levels I’d ride the ACMR trend from — and where the China risk caps it?
Join the Discord to find out! →ACM Research Q1 2026 8-K & earnings release (May 2026 — $231.3M rev +34%, 46.5% GM, $0.37 non-GAAP EPS, +65% new orders) · 2026 revenue-outlook 8-K (Jan 22 — $1.08–1.175B guide) · investor-relations Q&A 8-Ks (gross-margin 42–48% range, +65% Q1 order growth, ~6-mo delivery cycle) · backlog $1.27B (+34%) · Kerrisdale Capital ACMR update (Nov 2025 — ~70%+ discount to ACM Shanghai stake) + Kerrisdale/Steamboat activist letters & Hong Kong listing/anchor-investor interest (Apr 2026) · ACM Shanghai (SSE: 688082) live valuation (~¥183B market cap ≈ ~$25B; ACMR ~73.5% stake ≈ ~$18B) via Investing.com/StockAnalysis; independent NAV-discount analysis (~55–64% holdco discount; capital-control/SAFE/withholding mechanics) and an independent analyst’s public commentary (attribution omitted) · analyst targets via StockAnalysis/ChartMill/TickerNerd (median ~$70–74, Buy). Figures from SEC filings & releases; not live IBKR pricing.